March 3, 2021
The Chase Group’s track record for success continues with another executive placement secured for Arcturus Therapeutics. Entering a new stage in clinical development, Arcturus retained The Chase Group to identify a Head of Drug Safety to establish and create a strategy. The successful placement, serving as the drug safety and pharmacovigilance ambassador, is tasked with building the drug safety department at Arcturus and educating the organization on what is needed as they continue to grow and develop their versatile portfolio and cutting-edge technology for multiple disease areas. The Chase Group’s focused approach to the executive search process accompanied by its vast network of drug safety professionals allowed them to complete this search on an expedited time frame. The Chase Group never loses sight of the profound impact its services have on the future success of an organization and looks forward to a continued partnership with Arcturus Therapeutics as they grow and unlock the potential of mRNA medicines to provide patients with rare disease possibility and hope. To learn more about collaborating with The Chase Group to build your executive team, please contact ken@chasegroup.com.
